Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia
Adult acute lymphoblastic leukemia (ALL) has a poor overall survival compared with pediatric ALL where cure rates are observed in more than 90% of patients. The recent development of novel monoclonal antibodies targeting CD20, CD19, and CD22 has changed the long-term outcome of this disease, both in...
Main Authors: | Veronica A. Guerra, Elias J. Jabbour, Farhad Ravandi, Hagop Kantarjian, Nicholas J. Short |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-05-01
|
Series: | Therapeutic Advances in Hematology |
Online Access: | https://doi.org/10.1177/2040620719849496 |
Similar Items
-
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
by: Bachar Samra, et al.
Published: (2020-06-01) -
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
by: Nicholas J. Short, et al.
Published: (2019-02-01) -
Acute promyelocytic leukemia current treatment algorithms
by: Musa Yilmaz, et al.
Published: (2021-06-01) -
Evaluation and management of measurable residual disease in acute lymphoblastic leukemia
by: Iman Abou Dalle, et al.
Published: (2020-03-01) -
Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia
by: Diego Conde-Royo, et al.
Published: (2020-10-01)